Sign Up to like & get
recommendations!
1
Published in 2019 at "Journal of Medical Virology"
DOI: 10.1002/jmv.25536
Abstract: Direct acting antiviral (DAA) therapy against hepatitis C virus (HCV) increases sustained virologic response rates. Nevertheless, drug resistance has occasionally been associated with failure to DAA. However, the information about the prevalence of NS5A and…
read more here.
Keywords:
prevalence ns5a;
ns5a ns5b;
treatment;
rass ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2018 at "Scientific Reports"
DOI: 10.1038/s41598-018-34254-5
Abstract: Hepatitis C virus (HCV) vaccines, designed to augment specific T-cell responses, have been designated as an important aspect of effective antiviral treatment. However, despite the current satisfactory progress of these vaccines, extensive past efforts largely…
read more here.
Keywords:
ns5a ns5b;
hcv;
vaccine hcv;
immunoinformatics approaches ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Disease Markers"
DOI: 10.1155/2018/2514901
Abstract: Hepatitis C Virus (HCV) infection treatment has dramatically changed with the advent of direct-acting antiviral agents (DAAs). However, the efficacy of DAAs can be attenuated by the presence of resistance-associated substitutions (RASs) before and after…
read more here.
Keywords:
ns5a ns5b;
treatment;
infected patients;
resistance ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2025 at "Frontiers in Microbiology"
DOI: 10.3389/fmicb.2024.1498069
Abstract: Background HCV genotypes are 30–35% polymorphic at the nucleotide level, while subtypes within the same genotype differ by nearly 20%. Although previous studies have shown the immune escape potential of several mutations within the HCV…
read more here.
Keywords:
ns3 ns5a;
genotype subtype;
core ns3;
genotype ... See more keywords